TIDMAMS
RNS Number : 2886V
Advanced Medical Solutions Grp PLC
02 December 2019
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Acquisition of Biomatlante SA
- EUR8 million acquisition brings a wide range of
revenue-generating products in orthopaedic, spine, dental and
sports surgery
- Biomatlante provides access to an additional $0.5 billion international surgical market
- Provides a significant patent estate and a development pipeline of next-generation products
Winsford, UK, 2 December 2019: Advanced Medical Solutions Group
plc (AIM: AMS), the surgical and advanced wound care specialist
company, today announces that it has acquired French company
Biomatlante SA ("Biomatlante"), a well-established international
developer and manufacturer of innovative surgical biomaterial
technologies for EUR8 million (approximately GBP7 million) in cash,
with a potential further up to EUR0.3m due over the next two
years.
Acquisition rationale and benefits
The acquisition will strengthen AMS's product portfolio, R&D
pipeline, and market access. It provides the Group with a range of
revenue-generating surgical products and an R&D pipeline of
complementary biosurgical technologies and offers significant
growth potential in additional surgical markets estimated to be
worth $0.5 billion. The Acquisition is expected to be marginally
earnings enhancing in the first full year of ownership.
Biomatlante's biosurgical products, which are sold mainly in
Europe, are complementary to AMS's surgical product portfolio and
generated sales of more than EUR4 million in 2018. AMS anticipates
increasing the sales of these products in other jurisdictions
through its existing global commercial infrastructure, as well as
leveraging Biomatlante's established presence in France for the
Group's existing surgical product portfolio.
The R&D pipeline and platform technologies which AMS
acquired will broaden the Group's biosurgical technology offering
while also offering multiple synergies across the sales, marketing,
regulatory, operational divisions and R&D.
Terms of the transaction
The Acquisition is for an initial consideration of EUR8 million
(approximately GBP7 million) in cash, on a debt-free and cash-free
basis, to be funded from AMS's existing cash resources, which were
GBP64 million at 30 June 2019. A potential further up to EUR0.3m is
due over the next two years subject to the achievement of certain
new product approval milestones. The founder of Biomatlante, Doctor
Guy Daculsi, has entered into a consultancy agreement with AMS to
provide ongoing R&D and regulatory support until 31 December
2021.
Overview of Biomatlante
Biomatlante has a patent-protected technology platform with a
wide range of biomaterial products used in orthopaedic, spinal,
dental and sports surgery and a development pipeline of
next-generation products. The company's commercialised products,
which are approved for sale in over 50 countries worldwide, include
synthetic bone substitutes, collagen membranes and bioabsorbable
screws. In addition to the marketed products.
For its financial year ended 31 December 2018, Biomatlante
reported revenue of more than EUR4 million and a net profit of
approximately EUR0.2 million. As at 31 December 2018, Biomatlante
reported gross assets of approximately EUR2.4 million.
Biomatlante employs 36 full time staff and operates two
fully-equipped modern facilities close to Nantes in France, which
include manufacturing, innovation and administration over 1,330
square metres with eight dedicated clean rooms.
Biomatlante is ISO 13485 and MDSAP accredited with extensive
clinical evidence and is well prepared for the new European Medical
Device Regulation.
Commenting on the acquisition, Chris Meredith, CEO of AMS, said:
"This acquisition is in line with our strategy to acquire
technologies that are complementary to our surgical portfolio and
allow us to leverage our global routes to market. The acquisition
grants AMS access to multiple new markets, including the synthetic
bone substitutes market which is estimated at $0.5 billion. We are
excited to welcome the Biomatlante team to AMS and look forward to
working together with them to accelerate the commercial success
internationally and to continue to develop the Biomatlante
technology in a wide range of potential applications and
indications."
Commenting this acquisition, Chantal GOBIN-DACULSI, Co-founder
and President of Biomatlante said: "This is an important stragecic
step for Biomatlante and we are excited to become part of the AMS
group. AMS is a high quality global Company with the scale,
expertise and track record of realising the value of scienitific
innovation and rapidly growing the sales of marketed products. Our
product portfolios, product pipelines and geographic footprints are
highly complementary, and, as part of the AMS family, the know-how
of our team can be fully realised, allowing our pipeline of
synthetic bone substitutes to be commercialised on a global
scale."
- End -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Nicholas AMS@consilium-comms.com
Brown / Olivia Manser
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence / Patrick
Robb
About Advanced Medical Solutions Group plc - see
www.admedsol.com
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical and woundcare markets, focused on quality outcomes for
patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, and
internal fixation devices, which it markets under its brands
LiquiBand(R) , RESORBA(R) , and LiquiBandFix8(R) . AMS also
supplies wound care dressings such as silver alginates, alginates
and foams through its ActivHeal(R) brand as well as under white
label. In 2019, the Group acquired Sealantis, an Israeli-based
medical device company with a patent-protected internal sealant
technology platform.
AMS's products, manufactured in the UK, the Netherlands,
Germany, and the Czech Republic, are sold globally via a network of
multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, the Czech
Republic and Russia. The Group has R&D innovation hubs in the
UK and Germany, as well as the recently acquired R&D facility
in Israel. Established in 1991, the Group has approximately 650
employees. For more information please see www.admedsol.com
About Biomatlante
A pioneer in biologics solutions, Biomatlante develops,
manufactures and commercialises synthetic bone graft
technologies.
Biomatlante specializes in producing synthetic biomaterials for
bone regeneration and is a world leader in bone graft technologies,
selling its products in over 50 countries. Biomatlante's products
are routinely used in orthopaedics and trauma surgery, in spine,
ENT, maxillofacial and dental surgery.
Biomatlante collaborates closely with universities and research
centers across the world:
Amongst others, it collaborates with CNRS (French National
Center For Scientific Research), INSERM (National Institute of
Health and Medical Research) as well as several other national and
international universities. These partnerships enhance Biomatlante
ability to be in the frontier of innovation of new
biomaterials.
MBCP(R) Technology is a biphasic calcium phosphate synthetic
bone graft substitute platform with a unique micro and macroporous
structure that most closely resembles to the architecture of
natural human bone. MBCP(R) Technology products are available in
different shapes (granules, blocks and anatomical shapes),
injectable/moldable putty, resorbable osteosynthesis (based on
specific composite material combining MBCP(R) granules and
polymers), and MBCP(R) + smart scaffold for bone tissue engineering
to be associated with total bone marrow or expended mesenchymal
stem cells. Proven Osteogenic and osteoinductive properties are
related to the Biomatlante bioactive ceramic. EZ-Cure(R) collagenic
membrane, complementary product to the bone graft line, is proposed
to dental surgeon for a full surgical solution in maxillofacial
surgery.
https://www.biomatlante.com/en/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACQTTBFTMBIMMJL
(END) Dow Jones Newswires
December 02, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Advanced Medical Solutions (LSE:AMS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Advanced Medical Solutions (LSE:AMS)
Storico
Da Apr 2023 a Apr 2024